KR101384999B1 - Organogel Composition and Organogel Mask Pack using Thereof - Google Patents
Organogel Composition and Organogel Mask Pack using Thereof Download PDFInfo
- Publication number
- KR101384999B1 KR101384999B1 KR20120047564A KR20120047564A KR101384999B1 KR 101384999 B1 KR101384999 B1 KR 101384999B1 KR 20120047564 A KR20120047564 A KR 20120047564A KR 20120047564 A KR20120047564 A KR 20120047564A KR 101384999 B1 KR101384999 B1 KR 101384999B1
- Authority
- KR
- South Korea
- Prior art keywords
- organogel
- skin
- mask pack
- composition
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 24
- 239000008213 purified water Substances 0.000 claims description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 20
- 235000010445 lecithin Nutrition 0.000 claims description 20
- 239000000787 lecithin Substances 0.000 claims description 20
- 229940067606 lecithin Drugs 0.000 claims description 20
- 235000010418 carrageenan Nutrition 0.000 claims description 13
- 239000000679 carrageenan Substances 0.000 claims description 13
- 229920001525 carrageenan Polymers 0.000 claims description 13
- 229940113118 carrageenan Drugs 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 13
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 7
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 claims description 7
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 7
- 229920002581 Glucomannan Polymers 0.000 claims description 7
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 7
- 229940046240 glucomannan Drugs 0.000 claims description 7
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 abstract description 17
- 229920000642 polymer Polymers 0.000 abstract description 16
- 239000003349 gelling agent Substances 0.000 abstract description 9
- 150000005846 sugar alcohols Polymers 0.000 abstract description 7
- 125000000962 organic group Chemical group 0.000 abstract description 3
- 239000003921 oil Substances 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 28
- 239000000243 solution Substances 0.000 description 22
- 239000000499 gel Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 11
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 10
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
- 206010040954 Skin wrinkling Diseases 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 229920000297 Rayon Polymers 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000002964 rayon Substances 0.000 description 7
- 229940042585 tocopherol acetate Drugs 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 125000005250 alkyl acrylate group Chemical group 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 229920006037 cross link polymer Polymers 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000005191 phase separation Methods 0.000 description 5
- -1 polyol ester Chemical class 0.000 description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
- 229960003415 propylparaben Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000011034 Rubus glaucus Nutrition 0.000 description 4
- 235000009122 Rubus idaeus Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- LFESLSYSZQYEIZ-UHFFFAOYSA-N 3-octanoyloxybutyl octanoate Chemical compound CCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCC LFESLSYSZQYEIZ-UHFFFAOYSA-N 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000007651 Rubus glaucus Species 0.000 description 3
- 241000269821 Scombridae Species 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229940114374 butylene glycol dicaprylate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 235000020640 mackerel Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229960000342 retinol acetate Drugs 0.000 description 3
- 235000019173 retinyl acetate Nutrition 0.000 description 3
- 239000011770 retinyl acetate Substances 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- XWJBRBSPAODJER-UHFFFAOYSA-N 1,7-octadiene Chemical compound C=CCCCCC=C XWJBRBSPAODJER-UHFFFAOYSA-N 0.000 description 2
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- DCIFKIIQMLNANC-UHFFFAOYSA-N 3,3-diethyloctan-4-one Chemical compound CCCCC(=O)C(CC)(CC)CC DCIFKIIQMLNANC-UHFFFAOYSA-N 0.000 description 2
- PBFGMXZRJIUGKU-UHFFFAOYSA-N 3-decanoyloxybutyl decanoate Chemical compound CCCCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCCCC PBFGMXZRJIUGKU-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229940048053 acrylate Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Natural products OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- WPKYZIPODULRBM-UHFFFAOYSA-N azane;prop-2-enoic acid Chemical compound N.OC(=O)C=C WPKYZIPODULRBM-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940047670 sodium acrylate Drugs 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- DPPDPATYPQFYDL-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-4-methyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-5-thione Chemical compound O1C(CCN(C)C)CN(C)C(=S)C2=CC=CN=C21 DPPDPATYPQFYDL-UHFFFAOYSA-N 0.000 description 1
- IIFFFBSAXDNJHX-UHFFFAOYSA-N 2-methyl-n,n-bis(2-methylpropyl)propan-1-amine Chemical compound CC(C)CN(CC(C)C)CC(C)C IIFFFBSAXDNJHX-UHFFFAOYSA-N 0.000 description 1
- VAPQAGMSICPBKJ-UHFFFAOYSA-N 2-nitroacridine Chemical compound C1=CC=CC2=CC3=CC([N+](=O)[O-])=CC=C3N=C21 VAPQAGMSICPBKJ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- NDKYEUQMPZIGFN-UHFFFAOYSA-N Butyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCC NDKYEUQMPZIGFN-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000226556 Leontopodium alpinum Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000016594 Potentilla anserina Nutrition 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940057874 phenyl trimethicone Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 125000002523 retinol group Chemical group 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229950003786 rocastine Drugs 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical class [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
본 발명은 오르가노겔 마스크팩 조성물 및 이를 이용하여 제조된 오르가노겔 마스크 팩에 관한 것으로, 보다 상세하게는 오일, 오일 겔화제, 물, 다가알콜, 겔화고분자 및 피부 유효 성분을 포함하는 오르가노겔 조성물 및 이를 이용하여 제조된 오르가노겔 마스크 팩에 관한 것이다.
본 발명에 따른 오르가노겔 조성물에 있어서 오르가노겔 구조는 피부와 유사한 라멜라 구조를 갖기 때문에 피부 친화성이 향상되며, 이로 인해 피부 유효 성분의 전달이 용이하고 신속하게 일어날 수 있다. 또한, 본 발명에 따른 오르가노겔 조성물은 상대적으로 오일의 함량이 많기 때문에 다양한 유용성 피부 유효 성분의 전달이 용이하며, 피부 수분을 장기간 유지할 수 있어 경피 수분의 손실을 감소시킬 수 있다.The present invention relates to an organogel mask pack composition and an organogel mask pack prepared using the same, and more particularly, to an organo comprising an oil, an oil gelling agent, water, a polyhydric alcohol, a gelling polymer and a skin active ingredient. It relates to a gel composition and an organogel mask pack prepared using the same.
In the organogel composition according to the present invention, since the organogel structure has a lamellar structure similar to that of the skin, skin affinity is improved, and thus, the delivery of the active ingredient of the skin can be easily and quickly performed. In addition, since the organogel composition according to the present invention has a relatively high oil content, it is easy to deliver various useful skin active ingredients, and can maintain skin moisture for a long time, thereby reducing the loss of transdermal moisture.
Description
본 발명은 오르가노겔 조성물 및 이를 이용하여 제조된 오르가노겔 마스크 팩에 관한 것으로, 보다 상세하게는 오르가노겔에 포집된 피부 유효 성분의 경피 흡수성이 우수한 오르가노겔 조성물 및 이를 이용하여 제조된 오르가노겔 마스크 팩에 관한 것이다.
The present invention relates to an organogel composition and an organogel mask pack prepared using the same, and more particularly, to an organogel composition having excellent percutaneous absorption properties of the skin active ingredients collected in the organogel, An organogel mask pack.
"오르가노겔(organogel)" 이라는 용어는 오일 인 워터(oil in water) 역 마이크로에멀션의 겔화의 특이적 개념을 설명하기 위해 처음 사용되었다 (Luisi et al., Colloid & Polymer Science, 1990, vol. 268, pp. 356 - 374).
The term "organogel" was first used to describe the specific concept of gelation of oil in water inverse microemulsions (Luisi et al., Colloid & Polymer Science, 1990, vol. 268, pp. 356-374).
상기 용어는 나아가 최근 포스파티딜콜린이 풍부한 레시틴으로 안정화되는 2 가지 불혼화성 상들(oil in water)을 함유하는 겔화된 계, 주로 수소화된 계를 포함하는 범위까지 확장되었다 (Williman et al., Journal of Pharmaceutical Sciences, 1992, vol. 81, pp. 871 - 874 및 Schchipunov et al., Colloid Journal, 1995, vol. 57, pp. 556 - 560). 오르가노겔(organogel)은 피부구조와 유사한 라멜라 상을 가지며, 겔화제 없이도 겔 형태를 갖는 것이 특징이다.
The term has recently been extended to a range that includes gelled, mainly hydrogenated, systems containing two oil in water, stabilized with phosphatidylcholine-rich lecithin (Williman et al., Journal of Pharmaceutical Sciences , 1992, vol. 81, pp. 871-874 and Schchipunov et al., Colloid Journal, 1995, vol. 57, pp. 556-560). Organogel has a lamellar phase similar to the skin structure and is characterized by having a gel form without a gelling agent.
오르가노겔 중 특히 레시틴 오르가노겔은 피부와 유사한 라멜라 구조이기 때문에 피부 친화성을 가지며, 또한 장시간 피부에 대한 보습력을 유지할 수 있어서 화장료 조성물에 다양하게 적용되고 있다.
Among the organogels, in particular, the lecithin organogel has a skin affinity because of its lamellar structure similar to that of the skin, and has been applied to a variety of cosmetic compositions because it can maintain moisture for the skin for a long time.
한국특허 제0843155호에서는 레시틴(Lecithin)-오르가노겔(Organo Gel)구조인 레시틴겔로 비타민 C를 안정화시킨 피부 미백 화장료 조성물을 개시하고 있으며, 한국특허 제0824212호에서는 태반을 오르가노겔 내에 포집시켜 안정화시킨 피부보호용 화장료 조성물을 개시하고 있다.
Korean Patent No. 0843155 discloses a skin whitening cosmetic composition in which vitamin C is stabilized with a lecithin gel, which is a lecithin-organo gel structure. The cosmetic composition for skin protection stabilized by stabilizing is disclosed.
한편, 오르가노겔에 포집된 피부 유효 성분의 전달이 용이하고 신속하게 획득되는 보다 개선된 오르가노겔 조성물이 획득될 수 있다면 마스크 팩의 용도로써 유용할 것으로 기대된다.
On the other hand, it is expected to be useful as a mask pack if a more improved organogel composition can be obtained in which delivery of the skin active ingredient encapsulated in the organogel is easily and quickly obtained.
이에 본 발명의 한 측면은 오르가노겔에 포집된 피부 유효 성분이 용이하게 경피 흡수되도록 하는 오르가노겔 조성물을 제공하는 것이다.
Accordingly, one aspect of the present invention is to provide an organogel composition to facilitate the percutaneous absorption of the skin active ingredient trapped in the organogel.
본 발명의 또 다른 견지는 상기와 같은 오르가노겔 조성물을 이용하여 제조된 오르가노겔 마스크 팩을 제공하는 것이다.
Another aspect of the present invention is to provide an organogel mask pack prepared using the organogel composition as described above.
본 발명의 일 견지에 의하면, 오일, 오일 겔화제, 다가알콜, 물, 겔화 고분자 및 피부 유효 성분을 포함하는 오르가노겔 조성물이 제공된다.
According to one aspect of the present invention, there is provided an organogel composition comprising an oil, an oil gelling agent, a polyhydric alcohol, water, a gelling polymer and an active skin component.
본 발명의 다른 견지에 의하면, 상기 오르가노겔 조성물을 이용하여 제조된 오르가노겔 마스크 팩이 제공된다.
According to another aspect of the present invention, an organogel mask pack prepared using the organogel composition is provided.
본 발명에 따른 오르가노겔 조성물에 있어서 오르가노겔 구조는 피부와 유사한 라멜라 구조를 갖기 때문에 피부 친화성이 향상되며, 이로 인해 피부 유효 성분의 전달이 용이하고 신속하게 일어날 수 있다. 또한, 본 발명에 따른 오르가노겔 조성물은 상대적으로 오일의 함량이 많기 때문에 다양한 유용성 피부 유효 성분의 전달이 용이하며, 피부 수분을 장기간 유지할 수 있어 경피 수분의 손실을 감소시킬 수 있다.
In the organogel composition according to the present invention, since the organogel structure has a lamellar structure similar to that of the skin, skin affinity is improved, and thus, the delivery of the active ingredient of the skin can be easily and quickly performed. In addition, since the organogel composition according to the present invention has a relatively high oil content, it is easy to deliver various useful skin active ingredients, and can maintain skin moisture for a long time, thereby reducing the loss of transdermal moisture.
본 발명의 일 견지에 의하면, 오르가노겔에 포집된 피부 유효성분이 용이하게 경피 흡수될수 있는 오르가노겔 조성물이 제공된다.
According to one aspect of the invention, there is provided an organogel composition which can be easily transdermally absorbed skin active ingredient collected in the organogel.
보다 상세하게, 본 발명에 의한 오르가노겔 조성물은 오일, 오일 겔화제, 다가알콜, 물, 겔화고분자 및 피부유효 성분을 포함한다.
More specifically, the organogel composition according to the present invention includes an oil, an oil gelling agent, a polyhydric alcohol, water, a gelling polymer and an active ingredient of the skin.
본 발명에 사용될 수 있는 상기 오일은 이소프로필미리스테이트, 에틸라우레이트, 에틸미리스테이트, 이소프로필 팔미테이트, 시클로펜탄, 시클로옥탄, 트랜스-데칼린, n-펜탄, n-헥산, n-헥사데칸, 트리프로필아민, 1,7-옥타디엔, 부틸라우레이트, 시클로도데칸, 디부틸에테르, 이소옥탄, n-옥탄, 트리부틸아민, 트리이소부틸아민, 폴리올에스테르, 트리글리세라이드, 디글리세라이드, 모노글리세라이드, 디글리세라이드, 및 지방산 에스테르로 구성되는 그룹으로부터 선택되는 하나 이상일 수 있으며, 나아가 카프릴릭/카프릭트리글리세라이드, 부틸렌글라이콜디카프릴레이트/디카프레이트, 트리에틸헥사노인, 세틸에틸헥사노에이트, 이소프로필미리스테이트, 옥틸도데칸올 등의 에스테르계 오일; 리퀴드파라핀, 바세린, 하이드로제네이티드폴리데센, 스쿠알렌 등의 탄화수소계 오일; 마이크로리스탈린왁스, 비즈왁즈, 라놀린왁스 등의 왁스; 호호바오일, 아보카도오일, 아몬드오일, 올리브오일, 참기름, 밀배아유, 사플라워오일, 동백기름, 피마자유, 포도씨오일, 녹차씨오일, 마카다미아넛츠오일, 야자유, 로즈힙오일, 경화유, 아르간오일, 산자나무오일, 아르간트리커넬오일, 라벤더오일 등의 천연오일 및 사이클로메치콘, 페닐트리메치콘, 사이클로펜타실록산, 디메치콘 등의 실리콘오일로 구성되는 그룹으로부터 선택되는 최소 하나 이상의 혼합물일 수 있으나, 이로써 제한하는 것은 아니다. 바람직하게는 카프릴릭/카프릭트리글리세라이드, 부틸렌글라이콜디카프릴레이트/디카프레이트, 트리에틸헥사노인, 세틸에틸헥사노에이트, 이소프로필미리스테이트, 옥틸도데칸올 등의 에스테르계 오일을 사용한다. The oils that may be used in the present invention include isopropyl myristate, ethyl laurate, ethyl myristate, isopropyl palmitate, cyclopentane, cyclooctane, trans-decalin, n-pentane, n-hexane, But are not limited to, tripropylamine, tripropylamine, 1,7-octadiene, butyl laurate, cyclododecane, dibutyl ether, isooctane, n-octane, tributylamine, triisobutylamine, polyol ester, triglyceride, diglyceride, And may be at least one selected from the group consisting of ricin, carbohydrate, lipid, diglyceride, and fatty acid ester, and further may be caprylic / capric triglyceride, butyleneglycol dicaprylate / dicaprate, triethylhexanone, Ester-based oils such as neoate, isopropyl myristate and octyldodecanol; Hydrocarbon oils such as liquid paraffin, vaseline, hydrogenated polydecene and squalane; Waxes such as micro-stalin wax, beads wax and lanolin wax; Jojoba Oil, Avocado Oil, Almond Oil, Olive Oil, Sesame Oil, Wheat Germ Oil, Four Flower Oil, Camellia Oil, Castor Oil, Grape Seed Oil, Green Tea Seed Oil, Macadamia Nut Oil, Palm Oil, Rosehip Oil, Natural oils such as wood oil, argentine tree kernel oil and lavender oil, and silicone oils such as cyclomethicone, phenyltrimethicone, cyclopentasiloxane, dimethicone, and the like, It is not limited. Preferably, ester-based oils such as caprylic / capric triglyceride, butyleneglycolic dicaprylate / dicaprate, triethylhexanone, cetylethylhexanoate, isopropyl myristate and octyldodecanol are used do.
상기 오일은 마스크팩용 오르가노겔 조성물의 총 중량을 기준으로, 5 내지 45 중량%의 함량으로 포함될 수 있으며, 보다 바람직하게는 10 내지 30 중량%의 함량으로 포함된다. 상기 오일이 마스크팩용 오르가노겔 조성물의 총 중량을 기준으로 10중량% 미만으로 포함되는 경우에는 상대적으로 오일의 함량이 적어지게 되므로 목적하는 오르가노겔의 형성이 어렵고, 따라서 목적하는 피부유효성분의 경피 흡수율이 저하되는 경향이 있고, 45중량%를 초과하여 포함되는 경우에는 오일이 수상부와 분리되어 최종 마스크팩으로의 제조가 어려운 문제가 있다.
The oil may be included in an amount of 5 to 45% by weight, more preferably in an amount of 10 to 30% by weight, based on the total weight of the organogel composition for the mask pack. When the oil is included in less than 10% by weight based on the total weight of the organogel composition for the mask pack it is difficult to form the desired organogel because the content of the oil is relatively small, and thus the desired skin active ingredient If the transdermal absorption rate tends to be lowered and is included in an amount exceeding 45% by weight, the oil is separated from the aqueous phase, thereby making it difficult to manufacture the final mask pack.
상기 오일 겔화제는 레시틴, 플루로닉 레시틴, 소르비탄 지방산 에스테르, 젤라틴, L-리신(lysine), 리모넨, 및 폴리에틸렌으로 구성되는 그룹으로부터 선택되는 적어도 하나일 수 있으며, 이들의 혼합물도 이용할 수 있다.
The oil gelling agent may be at least one selected from the group consisting of lecithin, pluronic lecithin, sorbitan fatty acid esters, gelatin, L-lysine, limonene, and polyethylene, and mixtures thereof may also be used. .
상기 오일 겔화제는 마스크팩용 오르가노겔 조성물의 총 중량을 기준으로, 0.1 내지 10 중량%의 함량으로 포함될 수 있으며, 보다 바람직하게는 3 내지 7 중량%의 함량으로 포함된다. 상기 오일 겔화제가 마스크팩용 오르가노겔 조성물의 총 중량을 기준으로 0.1% 미만으로 첨가되는 경우에는 오일이 수상부와 혼합되지 않고 분리되는 문제가 있으며, 10중량%를 초과하여 포함되는 경우에는 최종적으로 획득되는 오르가노겔의 탄력이 떨어지는 문제가 있다.
The oil gelling agent may be included in an amount of 0.1 to 10% by weight, more preferably 3 to 7% by weight, based on the total weight of the organogel composition for the mask pack. When the oil gelling agent is added in less than 0.1% based on the total weight of the organogel composition for the mask pack, there is a problem that the oil is separated from the water phase without being mixed with the aqueous phase, and when included in excess of 10% by weight There is a problem that the elasticity of the obtained organogel falls.
본 발명에 사용될 수 있는 상기 다가알콜은 물과 함께 용매로서 사용되며, 글리세린, 에틸렌글리콜, 프로필렌글리콜, 디프로필렌글리콜, 부틸렌글리콜과 같은 다가알콜로 구성되는 그룹으로부터 선택되는 적어도 하나이거나 또는 이들의 혼합물일 수 있다.
The polyhydric alcohol which can be used in the present invention is used as a solvent with water, at least one selected from the group consisting of polyhydric alcohols such as glycerin, ethylene glycol, propylene glycol, dipropylene glycol, butylene glycol, or It may be a mixture.
상기 다가알콜은 오르가노겔 조성물의 총 중량을 기준으로 0.5 내지 35 중량%의 함량으로 포함될 수 있으며, 보다 바람직하게는 5 내지 15 중량%의 함량으로 포함된다. 0.5중량% 미만인 경우에는, 겔화 고분자의 분산이 어려운 경향이 있고, 35중량%를 초과하는 경우에는 상대적으로 물의 함량이 적어지기 때문에 시간이 지나면서 겔의 강도가 저하되고 피부에 적용 시 끈적임이 과도하게 증가하는 경향이 있다.
The polyhydric alcohol may be included in an amount of 0.5 to 35% by weight based on the total weight of the organogel composition, more preferably in an amount of 5 to 15% by weight. If it is less than 0.5% by weight, the dispersion of the gelling polymer tends to be difficult, and if it is more than 35% by weight, the gel content decreases over time because the water content is relatively low, and the stickiness is excessive when applied to the skin. Tends to increase.
한편, 본 발명의 오르가노겔에 포함되는 물은 잔부의 양으로 포함되며, 즉 상기 물은 전체 조성물이 100중량%가 되는 최종의 양으로 첨가된다. 한편, 물은 물 이외의 각 성분이 용이하게 용해될 수 있는 정도로 나누어 첨가하는 것이 바람직하다.
On the other hand, the water contained in the organogel of the present invention is included in the amount of the balance, that is, the water is added in the final amount of 100% by weight of the total composition. On the other hand, it is preferable to add water dividingly to the extent that each component other than water can be melt | dissolved easily.
상기 겔화고분자는 갈락토만난, 글루코만난, 구아껌, 로카스트 빈 껌, 플루로닉, 아가, 알긴, 카라기난, 잔탄, 겔란, 젤라틴, 메틸셀룰로오스, 셀룰로오스, 카르복시메틸셀룰로오스, 및 히드록시에틸셀룰로오스와 같은 천연 당류; 폴리아크릴레이트 또는 그의 염, 폴리메타크릴산, 카르복시비닐폴리머, 폴리비닐알코올, 폴리아크릴아미드, 폴리에틸렌옥시드, 폴리에틸렌이민, 폴리비닐피롤리돈과 같은 친수성 겔화제로 구성되는 그룹으로부터 선택되는 최소 하나 이상의 혼합물이다.
The gelling polymer may be selected from the group consisting of galactomannan, glucomannan, guar gum, locust bean gum, pluronic, agar, algin, carrageenan, xanthan, gellan, gelatin, methylcellulose, cellulose, carboxymethylcellulose and hydroxyethylcellulose Natural sugars; At least one member selected from the group consisting of polyacrylates or salts thereof, hydrophilic gelling agents such as polymethacrylic acid, carboxyvinyl polymer, polyvinyl alcohol, polyacrylamide, polyethylene oxide, polyethyleneimine, polyvinylpyrrolidone / RTI >
상기 겔화고분자는 본 발명의 오르가노겔 조성물의 총 중량을 기준으로, 0.1 내지 10 중량%의 함량으로 포함될 수 있으며, 보다 바람직하게는 0.5 내지 5 중량%의 함량으로 포함된다. 상기 수용성 중합체가 오르가노겔 조성물의 총 중량을 기준으로 0.1중량% 미만으로 첨가되는 경우에는 겔의 형태 유지는 가능하지만 겔의 강도가 높고 유연성이 낮아져 피부에 밀착성이 떨어지고, 20중량%을 초과하여 첨가되는 경우에는 겔이 늘어져 형태 유지가 어렵고 탄력성이 떨어져 제조에 어려움이 있는 문제가 있다.
The gelling polymer may be included in an amount of 0.1 to 10% by weight, more preferably 0.5 to 5% by weight, based on the total weight of the organogel composition of the present invention. When the water-soluble polymer is added at less than 0.1% by weight based on the total weight of the organogel composition, it is possible to maintain the shape of the gel, but the strength of the gel is high and the flexibility is low, resulting in poor adhesion to the skin and exceeding 20% by weight. When added, the gel is liable to be difficult to maintain the shape and elasticity is difficult to manufacture a problem.
본 발명에서는 최소 2개 이상의 겔화고분자를 첨가하여 가교된 매트릭스를 얻을 수 있으며, 이와 같이 제조된 매트릭스는 피부미용 팩으로 사용되는 경우 오르가노겔의 형태 유지에 바람직하다.
In the present invention, a crosslinked matrix may be obtained by adding at least two gelling polymers, and the matrix thus prepared is preferable for maintaining the form of the organogel when used as a skin care pack.
가장 바람직하게는, 갈락토만난, 글루코만난, 구아껌, 로카스트 빈 껌, 및 플루로닉으로 구성된 그룹으로부터 선택되는 가지형 고분자와 아가, 알긴, 카라기난, 잔탄, 겔란, 및 젤라틴으로 구성되는 그룹으로부터 선택되는 전해질 고분자를 각각 최소 1종 이상 혼합하는 것이 바람직하다.
Most preferably from a group consisting of a branched polymer selected from the group consisting of galactomannan, glucomannan, guar gum, rocastine gum, and pluronic and agar, algin, carrageenan, xanthan, gellan, and gelatin It is preferable to mix at least one selected electrolyte polymer.
상기 전해형 겔화 고분자는 본 발명의 조성물이 평상시 상온에서(약 20℃내외), 바람직하게는 0-30℃의 온도에서 겔 상태로 유지되도록 하는 역할을 하고, 가지형 겔화 고분자는 온도상승 시, 즉 10-50℃, 바람직하게는 체온부근인 약 30-40℃에서, 본 발명의 오르가노겔이 유동상태로 변하여 피부에 효과적으로 적용될 수 있게 하는 역할을 할 수 있다.
The electrolytic gelling polymer serves to maintain the composition of the present invention at normal room temperature (about 20 ℃), preferably in a gel state at a temperature of 0-30 ℃, branched gelling polymer when the temperature rise, That is, at 10-50 ° C., preferably at about 30-40 ° C. near the body temperature, the organogel of the present invention may be changed into a fluid state, and may be effectively applied to the skin.
이때, 상기 가지형 겔화 고분자 및 전해형 겔화 고분자는 조성물의 총 중량을 기준으로 각각 0.05-10중량% 및 0.05-5중량%로 함유되는 것이 바람직하며, 만일 이러한 범위를 벗어나는 경우, 겔이 형성되지 않거나 온도를 상승시켜도 겔상태가 유동상태로 변화하는 현상이 일어나지 않을 수 있다.
At this time, it is preferable that the branched gelling polymer and the electrolytic gelling polymer are contained in an amount of 0.05-10 wt% and 0.05-5 wt%, respectively, based on the total weight of the composition, and if it is outside this range, Or when the temperature is raised, the phenomenon that the gel state changes into the fluid state may not occur.
또한, 본 발명의 조성물에 있어서 필요에 따라 상기 겔화고분자는 아크릴계 중합체, 스타이렌계 공중합체 및 이들의 혼합물로부터 선택되는 적어도 하나 이상의 가교제와 혼합될 수 있으며, 상기 가교제로서 바람직한 성분은 예를 들어, 소듐아크릴레이트/C10-30알킬아크릴레이트크로스폴리머(Sodium Acrylates/C10-30 Alkyl Acrylate Crosspolymer) 또는 포타슘아크릴레이트/C10-30알킬아크릴레이트크로스폴리머(Potassium Acrylates/C10-30 Alkyl Acrylate Crosspolymer), 아크릴레이트/에틸헥실아크릴레이트/헤마/스타이렌공중합체(Acrylates/Ethylhexyl Acrylate/HEMA/StyreneCopolymer), 부틸렌/에틸렌/스타이렌공중합체(Butylene/Ethylene/Styrene Copolymer), 암모늄아크릴레이트/메틸스타이렌/스타이렌공중합체(Ammonium Acrylates/Methyl Styrene/Styrene Copolymer), 스타이렌/브이피공중합체(Styrene/VP Copolymer) 및 스타이렌/아크릴레이트공중합체(Styrene/Acrylates Copolymer)로 이루어진 군에서 선택된 1종 또는 2종 이상을 들 수 있다.
In addition, in the composition of the present invention, the gelling polymer may be mixed with at least one or more crosslinking agents selected from acrylic polymers, styrene copolymers, and mixtures thereof, and a component preferred as the crosslinking agent may be, for example, sodium. Sodium Acrylates / C10-30 Alkyl Acrylate Crosspolymer or Potassium Acrylate / C10-30 Alkyl Acrylate Crosspolymer, Acrylate / C10-30 Alkyl Acrylate Crosspolymer Ethylhexyl Acrylate / HEMA / Styrene Copolymer, Butylene / Ethylene / Styrene Copolymer, Ammonium Acrylate / Styrene Copolymer Ammonium Acrylates / Methyl Styrene / Styrene Copolymer, Styrene / VP Copolymer and Styrene / One or two or more selected from the group consisting of acrylate copolymers (Styrene / Acrylates Copolymer) may be mentioned.
상기 가교제가 첨가되는 경우 이와 같은 가교제는 본 발명의 오르가노 겔의 물성을 더욱 개선시키는 역할을 할 뿐만 아니라, 막을 얇게 형성할 수 있도록 하여 피부에 사용 시 말착력을 보다 우수하게 하고 수분을 효과적으로 유지시켜줄 수 있으며, 나아가 본 발명의 오르가노 겔에 부드러운 감촉을 제공하는 역할을 할 수도 있다. 상기 가교제는 오르가노겔 조성물의 총 중량을 기준으로 0.01 내지 5 중량%로 첨가될 수 있다.
When the cross-linking agent is added, such a cross-linking agent not only serves to further improve the physical properties of the organo gel of the present invention, but also to form a thin film to better adhere to when used on the skin and maintain moisture effectively It may also serve to provide a soft texture to the organo gel of the present invention. The crosslinking agent may be added at 0.01 to 5% by weight based on the total weight of the organogel composition.
나아가, 상기 마스크팩용 오르가노겔 조성물에 포함될 수 있는 피부 유효성분은 레티놀, 레티닐팔미테이트, 레티닐 아세테이트, 레티노인산, 코엔자임 큐텐, 엘라스틴, 콜라겐, 히알루론산, 세라마이드, 콜라겐, 카페인, 키토산, 아스코르빈산, 아스코르빌글루코사이드, 알파비사볼롤, 토코페롤, 토코페롤아세테이트, 알부틴, 니아신아마이드, 아데노신, 레티놀아세테이트, 비타민 A, D, E, 및 그 외 천연추출물로 구성되는 그룹으로부터 선택되는 적어도 하나 이상일 수 있으며, 바람직하게는 이들의 혼합물을 이용할 수 있다.
Furthermore, the skin active ingredient that may be included in the organogel composition for the mask pack is retinol, retinyl palmitate, retinyl acetate, retinoic acid, coenzyme qtene, elastin, collagen, hyaluronic acid, ceramide, collagen, caffeine, chitosan, ascorbic acid At least one selected from the group consisting of binic acid, ascorbylglucoside, alphabisabolol, tocopherol, tocopherol acetate, arbutin, niacinamide, adenosine, retinol acetate, vitamins A, D, E, and other natural extracts; It is preferable to use a mixture thereof.
본 발명에 따른 마스크팩용 오르가노겔 조성물을 이용하여 마스크팩을 제조하는 경우 특히, 토코페롤아세테이트, 레티놀아세테이트, 비타민 A, D, E, 세라마이드, 코엔자임큐텐, 및 알파비사볼롤과 같은 유용성 성분 경피 투과 흡수율이 현저하게 개선될 수 있다.
When preparing a mask pack using the organogel composition for a mask pack according to the present invention, in particular, useful components such as tocopherol acetate, retinol acetate, vitamin A, D, E, ceramide, coenzymecuten, and alpha bisabolol, transdermal absorption rate This can be significantly improved.
상기 천연추출물은 알로에, 녹차, 인삼, 홍삼, 목초액, 솔잎, 은행잎, 프로폴리스, 뽕잎, 누에, 달팽이 점액, 카카두플럼, 카무카무, 야사이야자, 스쿠알란, 캐비어, 브로콜리, 블루베리, 위치하젤, 아세로라, 클로렐라, 망고스틴, 구아바, 산수유, 당근, 카페인, 하마멜리스, 스피룰리나, 연어알, 감태, 자이언트켈프, 곤포, 마치현, 파래, 우뭇가사리, 뽕 나무 뿌리, 라즈베리, 산딸기, 톳, 모자반, 에델바이스, 카모마일, 라벤더, 페퍼민트, 유칼립투스, 레몬밤, 오레가노, 티트리, 황금, 어성초, 산자나무, 및 유자로 이루어진 그룹으로부터 선택되는 1종 이상인 것이 바람직하다.
The natural extract may be selected from the group consisting of aloe, green tea, ginseng, red ginseng, vinegar, ginkgo leaf, propolis, mulberry leaf, silkworm, snail mucilage, kakaduplum, camucam, yashiyaki, squalane, caviar, broccoli, , Raspberry, raspberry, raspberry, mackerel, mackerel, mackerel, mulberry root, raspberry, carrot, caffeine, Hamamelis, Spirulina, salmon roe, It is preferably at least one selected from the group consisting of edelweiss, chamomile, lavender, peppermint, eucalyptus, lemon balm, oregano, tea tree, golden,
상기 피부 유효성분은 전체 조성물의 중량을 기준으로, 0.05 내지 10 중량%의 함량으로 포함될 수 있으며, 보다 바람직하게는 2 내지 5 중량%의 함량으로 포함된다. 상기 피부 유효성분이 전체 조성물의 중량을 기준으로 0.1중량% 미만으로 포함되는 경우에는 피부미용 효과가 미미하며, 20중량%를 초과하여 포함되는 경우에는 피부 자극이 발생할 수 있다.
The skin active ingredient may be contained in an amount of 0.05 to 10% by weight, more preferably 2 to 5% by weight, based on the weight of the whole composition. When the skin active ingredient is included in less than 0.1% by weight based on the total weight of the composition, the skin beauty effect is insignificant, and when included in excess of 20% by weight may cause skin irritation.
또한, 용도 및 필요에 따라 구연산, 포타슘하이드록사이드 및 알지닌과 같은 pH조절제; 메틸파라벤, 프로필파라벤과 같은 파라벤류 및 페녹시에탄올과 같은 방부제; 2Na EDTA와 같은 금속이온봉쇄제; 베타인, 소르비톨, 1,2-헥산디올, 에리쓰리톨 등과 같은 보습제 등의 기타 첨가제가 첨가될 수 있다.
PH adjusters such as citric acid, potassium hydroxide and arginine, depending on the application and necessity; Preservatives such as parabens such as methylparaben, propylparaben and phenoxyethanol; Metal ion sequestrants such as 2Na EDTA; Other additives such as betaine, sorbitol, 1,2-hexanediol, moisturizers such as erythritol and the like may be added.
상기 기타 첨가제는 본 발명의 오르가노겔 조성물의 총 중량을 기준으로, 0.01 내지 10중량%의 함량으로 포함될 수 있으며, 보다 바람직하게는 0.05 내지 5 중량%의 함량으로 포함된다.
The other additives may be included in an amount of 0.01 to 10% by weight, and more preferably 0.05 to 5% by weight, based on the total weight of the organogel composition of the present invention.
본 발명에 따른 오르가노겔은 피부와 유사한 라멜라 구조를 가지기 때문에 피부 친화성이 개선되며, 이로 인해 피부 유효 성분이 오르가노겔에서부터 피부로 용이하고 신속하게 전달될 수 있다. 나아가, 본 발명에 따른 오르가노겔은 상대적으로 오일의 함량이 많아 유용성 피부 유효 성분의 전달에 용이하며, 피부 수분을 장기간 유지할 수 있어 경피수분손실을 감소시킬 수 있다.
Since the organogel according to the present invention has a lamellar structure similar to that of the skin, skin affinity is improved, thereby allowing the skin active ingredient to be easily and quickly transferred from the organogel to the skin. Furthermore, the organogel according to the present invention has a relatively high oil content and is easy to deliver useful skin active ingredients, and can maintain skin moisture for a long time, thereby reducing transdermal moisture loss.
한편, 본 발명에 따른 오르가노겔 조성물을 이용한 마스크팩은 하기와 같은 공정에 의해 제조될 수 있다.
On the other hand, the mask pack using the organogel composition according to the present invention can be prepared by the following process.
먼저, 일부 물에 필요한 경우 기타 첨가제를 혼합하고 약 70 내지 80℃로 가열하여 성분을 용해시킨다. 여기에, 잔부의 물에 겔화고분자, 피부미용성분, 다가 알콜을 첨가하여 용해한 혼합물을 추가하여 혼합하여 균일한 용액이 되도록 교반한다. 이 때, 필요에 따라 가교제를 추가로 첨가할 수 있다. 상기 온도가 70 ℃ 미만인 경우에는 물에 첨가되는 성분이 완전히 용해되지 않고, 80 ℃ 초과인 경우에는 일부 첨가제나 천연성분의 안정성이 저하될 수 있다.
First, if necessary for some water, other additives are mixed and heated to about 70-80 ° C. to dissolve the components. Here, the mixture obtained by adding the gelled polymer, the skin beauty ingredient, and the polyhydric alcohol to the remainder of the water was added, mixed, and stirred to form a uniform solution. At this time, a crosslinking agent can be further added as needed. If the temperature is less than 70 ℃ component is added to water is not completely dissolved, if more than 80 ℃ may be the stability of some additives or natural components.
상기 본 발명의 오르가노겔의 제조 시 물은 전체 조성물이 100중량%가 되는 최종의 양으로, 각 성분이 용이하게 용해될 수 있는 정도로 적절하게 나누어 첨가할 수 있다.
In the preparation of the organogel of the present invention, water may be added in an appropriate amount so that each component may be easily dissolved in the final amount of the total composition to 100% by weight.
별도로, 약 70 내지 80℃로 가열된 오일, 오일 겔화제를 첨가한 혼합물을 상기 혼합 용액에 교반하면서 천천히 적가하여 오르가노겔 용액을 제조한다. 이 때 필요한 경우 방부제와 같은 기타 첨가제가 추가로 포함될 수 있다. 상기 혼합 시 온도가 70 ℃ 미만인 경우에는 수상부와 유상부가 용이하게 혼합되지 않아 오르가노겔의 제조가 어려우며, 온도가 80 ℃를 초과하는 경우에는 수상부와 유상부에 첨가된 물질의 안정성이 저하될 우려가 있다.
Alternatively, the oil, oil gelling agent is heated to about 70 to 80 ℃ The added mixture is slowly added dropwise to the mixed solution with stirring to prepare an organogel solution. Other additives such as preservatives may be further included if required. When the temperature is less than 70 ℃ during mixing, the aqueous phase and the oil phase is not easily mixed, it is difficult to manufacture the organogel, if the temperature exceeds 80 ℃, the stability of the material added to the water phase and the oil phase is lowered There is concern.
이와 같이 획득되는 상기 오르가노겔 용액을 지지체에 코팅한 다음, 상온에서 냉각시키고, 원하는 모양으로 성형하여 오르가노겔 마스크팩을 제조할 수 있다.
The organogel solution thus obtained is coated on a support, then cooled to room temperature, and molded into a desired shape to prepare an organogel mask pack.
상기 지지체는 나일론, 레이온, 부직포 등이 사용될 수 있으며, 바람직하게는 레이온 망목 직물을 이용할 수 있다.
The support may be nylon, rayon, nonwoven fabric or the like, and preferably a rayon mesh fabric may be used.
상기 오르가노겔 마스크팩을 얼굴, 눈밑, 볼, 턱, 목 등 신체 부위에 적합하게 원하는 모양으로 성형하여 최종적인 오르가노겔 마스크팩을 획득할 수 있으며, 나아가 상기 오르가노겔 마스크팩의 양면은 필름으로 보호될 수 있다.
The organogel mask pack may be molded into a desired shape suitable for body parts such as face, eyes, cheeks, chin, neck, etc. to obtain a final organogel mask pack. Furthermore, both sides of the organogel mask pack may be It can be protected with a film.
지지체 상에 코팅되는 상기 오르가로겔 조성물은 0.01 내지 50mm의 두께인 것이 바람직하며, 0.01mm 미만인 경우 두께가 얇아 피부에 부착 시 겔이 찢어지는 문제가 발생할 수 있으며, 겔에 포함되는 피부유효성분의 양이 적으므로 피부에 이들이 충분히 전달되지 못하는 문제가 있으며, 50mm을 초과하는 경우에는 겔이 과도하게 두꺼워지기 때문에 피부에 대한 밀착성이 떨어지는 문제가 있다.
The organogel composition coated on the support is preferably a thickness of 0.01 to 50mm, if the thickness is less than 0.01mm may cause a problem that the gel is torn when attached to the skin, the active ingredient included in the gel Since the amount is small, there is a problem that they are not sufficiently delivered to the skin, and if it exceeds 50mm, because the gel is excessively thick, there is a problem of poor adhesion to the skin.
이하, 구체적인 실시예를 통해 본 발명을 보다 구체적으로 설명한다. 하기 실시에는 본 발명의 이해를 돕기 위한 예시에 불과하며, 본 발명의 범위가 이에 한정되는 것은 아니다.
Hereinafter, the present invention will be described more specifically by way of specific examples. The following examples are given for the purpose of helping to understand the present invention, but the scope of the present invention is not limited thereto.
실시예Example
<<
실시예Example
>>
1. One.
오르가노겔Organogel
마스크팩의Mask pack
제조 Produce
실시예Example 1 및 2 1 and 2
먼저, 제1 정제수에, EDTA 2Na, 베타인 및 메틸파라벤을 혼합하고 약 75 내지 80℃로 가열하여 성분을 용해시켰다. 여기에, 제2 정제수에 니아신아미이드, 부틸렌글리콜, 글리세린, 카라기난 및 로카스트빈 검을 혼합한 용액을 추가하여 혼합하였다. 실시예 1 및 2의 경우에 있어서, 상기 성분의 각 함량은 하기 표 1에 기재된 바와 같다.
First, EDTA 2Na, betaine and methylparaben were mixed in the first purified water and heated to about 75 to 80 ° C. to dissolve the components. Here, the solution which mixed niacinamide, butylene glycol, glycerin, carrageenan, and locustvin gum was added and mixed to 2nd purified water. In the case of Examples 1 and 2, the respective contents of the components are as described in Table 1 below.
별도로, 75 내지 80℃로 가열된 카프릴릭/카프릭 트리글리세리드(Caprylic/Capric Triglyceride, MCT), 레시틴 및 프로필파라벤의 혼합물을 상기 용액에 교반하면서 천천히 적가하여 오르가노겔 용액을 제조하였다.
Separately, a mixture of Caprylic / Capric Triglyceride (MCT), lecithin and propylparaben heated to 75-80 ° C. was slowly added dropwise with stirring to the solution to prepare an organogel solution.
상기 오르가노겔 용액을 레이온 망목 직물을 심지로 넣고 양면으로 코팅한 다음, 원하는 모양으로 성형하여 오르가노겔 마스크팩을 제조하였다.
The organogel solution was coated with a rayon mesh fabric as a wick and coated on both sides, and then molded into a desired shape to prepare an organogel mask pack.
실시예Example 3 및 4 3 and 4
먼저, 제1 정제수에, EDTA 2Na, 소르비톨, 메틸파라벤 및 소듐아크릴레이트/C10-30알킬아크릴레이트크로스폴리머을 혼합하고 약 75 내지 80℃로 가열하여 성분을 용해시켰다. 여기에, 제2 정제수에 토코페롤아세테이트, 글리세린, 카라기난 및 로카스트빈 검을 혼합한 용액을 추가하여 혼합하였다. 실시예 3 및 4의 경우에 있어서, 상기 성분의 각 함량은 하기 표 2에 기재된 바와 같다.
First, EDTA 2Na, sorbitol, methylparaben and sodium acrylate / C 10-30 alkyl acrylate crosspolymer were mixed in the first purified water and heated to about 75 to 80 ° C. to dissolve the components. Here, the solution which mixed tocopherol acetate, glycerin, carrageenan, and locustbin gum was added and mixed to 2nd purified water. In the case of Examples 3 and 4, the respective contents of the components are as shown in Table 2 below.
별도로, 75 내지 80℃로 가열된 부틸렌글라이콜디카프릴레이트/디카프레이트 또는 트리에틸헥사노인 및 레시틴의 혼합물을 상기 용액에 교반하면서 천천히 적가하여 오르가노겔 용액을 제조하였다.
Separately, an organogel solution was prepared by dropwise addition of butyleneglycoldicaprylate / dicaprate or a mixture of triethylhexanoin and lecithin heated to 75-80 ° C. with stirring.
상기 오르가노겔 용액을 레이온 망목 직물을 심지로 넣고 양면으로 코팅한 다음, 원하는 모양으로 성형하여 오르가노겔 마스크팩을 제조하였다.
The organogel solution was coated with a rayon mesh fabric as a wick and coated on both sides, and then molded into a desired shape to prepare an organogel mask pack.
실시예Example 5 및 6 5 and 6
먼저, 제1 정제수에, EDTA 2Na, 소르비톨, 부틸렌/에틸렌/스타이렌공중합체 및 메틸파라벤을 혼합하고 약 75 내지 80℃로 가열하여 성분을 용해시켰다. 여기에, 제2 정제수에 알파비사볼롤, 글리세린, 카라기난 및 글루코만난을 혼합한 용액을 추가하여 혼합하였다. 실시예 5 및 6의 경우에 있어서, 상기 성분의 각 함량은 하기 표 3에 기재된 바와 같다.
First, EDTA 2Na, sorbitol, butylene / ethylene / styrene copolymer and methylparaben were mixed in the first purified water and heated to about 75 to 80 ° C. to dissolve the components. Here, the solution which mixed alpha bisabolol, glycerin, carrageenan, and glucomannan to the 2nd purified water was added and mixed. In the case of Examples 5 and 6, each content of the above components is as described in Table 3 below.
별도로, 75 내지 80℃로 가열된 세틸에틸헥사노에이트 또는 이소프로필미리스테이트, 및 레시틴 또는 플루로닉 레시틴의 혼합물을 상기 용액에 교반하면서 천천히 적가하여 오르가노겔 용액을 제조하였다.
Separately, a mixture of cetylethylhexanoate or isopropyl myristate and lecithin or pluronic lecithin heated to 75-80 ° C. was slowly added dropwise with stirring to the solution to prepare an organogel solution.
상기 오르가노겔 용액을 레이온 망목 직물을 심지로 넣고 양면으로 코팅한 다음, 원하는 모양으로 성형하여 오르가노겔 마스크팩을 제조하였다.
The organogel solution was coated with a rayon mesh fabric as a wick and coated on both sides, and then molded into a desired shape to prepare an organogel mask pack.
실시예Example 7 및 8 7 and 8
먼저, 제1 정제수에, EDTA 2Na, 소르비톨, 부틸렌/에틸렌/스타이렌공중합체 및 메틸파라벤을 혼합하고 약 75 내지 80℃로 가열하여 성분을 용해시켰다. 여기에, 제2 정제수에 알파비사볼롤, 글리세린, 글루코만난 및 겔란 또는 카라기난을 혼합한 용액을 추가하여 혼합하였다. 실시예 7 및 8의 경우에 있어서, 상기 성분의 각 함량은 하기 표 4에 기재된 바와 같다.
First, EDTA 2Na, sorbitol, butylene / ethylene / styrene copolymer and methylparaben were mixed in the first purified water and heated to about 75 to 80 ° C. to dissolve the components. Here, the solution which mixed alpha bisabolol, glycerin, glucomannan and gellan or carrageenan was added and mixed to 2nd purified water. In the case of Examples 7 and 8, each content of the above components is as described in Table 4 below.
별도로, 75 내지 80℃로 가열된 세틸에틸헥사노에이트 또는 이소프로필미리스테이트, 및 레시틴 또는 플루로닉 레시틴의 혼합물을 상기 용액에 교반하면서 천천히 적가하여 오르가노겔 용액을 제조하였다.
Separately, a mixture of cetylethylhexanoate or isopropyl myristate and lecithin or pluronic lecithin heated to 75-80 ° C. was slowly added dropwise with stirring to the solution to prepare an organogel solution.
상기 오르가노겔 용액을 레이온 망목 직물을 심지로 넣고 양면으로 코팅한 다음, 원하는 모양으로 성형하여 오르가노겔 마스크팩을 제조하였다.
The organogel solution was coated with a rayon mesh fabric as a wick and coated on both sides, and then molded into a desired shape to prepare an organogel mask pack.
비교예Comparative Example 1 및 2 1 and 2
먼저, 제1 정제수에, EDTA 2Na, 베타인 및 메틸파라벤을 혼합하고 약 75 내지 80℃로 가열하여 성분을 용해시켰다. 여기에, 제2 정제수에 토코페롤아세테이트, 글리세린, 로카스트빈 검 및 카라기난을 혼합한 용액을 추가하여 혼합하였다. 비교예 1 및 2의 경우에 있어서, 상기 성분의 각 함량은 하기 표 5에 기재된 바와 같다.
First, EDTA 2Na, betaine and methylparaben were mixed in the first purified water and heated to about 75 to 80 ° C. to dissolve the components. Here, the solution which mixed tocopherol acetate, glycerin, locust bean gum, and carrageenan was added and mixed to 2nd purified water. In the case of Comparative Examples 1 and 2, the respective contents of the components are as described in Table 5 below.
별도로, 75 내지 80℃로 가열된 MTC, 레시틴 및 프로필파라벤의 혼합물을 상기 용액에 교반하면서 천천히 적가하여 오르가노겔 용액을 제조하였다.
Separately, a mixture of MTC, lecithin and propylparaben heated to 75-80 ° C. was slowly added dropwise with stirring to the solution to prepare an organogel solution.
상기 오르가노겔 용액을 레이온 망목 직물을 심지로 넣고 양면으로 코팅한 다음, 원하는 모양으로 성형하여 오르가노겔 마스크팩을 제조하였다.
The organogel solution was coated with a rayon mesh fabric as a wick and coated on both sides, and then molded into a desired shape to prepare an organogel mask pack.
2.2.
오르가노겔Organogel
마스크팩의Mask pack
물성 평가 Property evaluation
상기 실시예 및 비교예에서 제조된 오르가노겔 마스크팩의 물성을 측정하였으며, 그 결과는 하기 표에 나타내었다.
The physical properties of the organogel mask packs prepared in Examples and Comparative Examples were measured, and the results are shown in the following table.
(1) 보습도 평가(1) Evaluation of moisturizing degree
제조된 오르가노겔을 직경 10 mm 크기의 원형으로 잘라서 초기 중량을 측정한 다음, 이를 30분 동안 건강한 여성 20명의 팔 상박의 내측에 부착한 후 떼어 내어 무게를 측정하여 그 차이를 계산하였다. 수분의 증발을 막기 위해 오르가노겔과 같은 크기의 비닐을 덮어 고정하였다.
The organogel was cut into a 10 mm diameter circle, and the initial weight thereof was measured. Then, the organogel was attached to the inside of the upper arm of 20 healthy women for 30 minutes, and then detached. In order to prevent evaporation of moisture, a vinyl of the same size as the organogel was covered and fixed.
수분보유량을 비침습적으로 인비보(in vivo) 상태에서 커패시턴스(capacitance)를 측정하는 기기인 Corneometer CM 825 (Courage and Khazaka, Germany)를 이용하여 오르가노겔을 붙인 피부 영역의 보습력을 측정하였으며, 경피수분손실량 (transepidermal water loss, 이하 TEWL)을 측정하는 장치인 Tewarmeter TM210 (Courage and khazaka, Germany)을 이용하여 수분손실량 (g/m2h)을 측정하였다.
Moisturizing power of organogel-attached skin was measured using Corneometer CM 825 (Courage and Khazaka, Germany), a device that measures capacitance in vivo in a non-invasive manner. The amount of water loss (g / m 2 h) was measured using Tewarmeter TM210 (Courage and khazaka, Germany), a device for measuring transepidermal water loss (TEWL).
상기 측정은20명에 대해 각각 수행하여, 이들로부터 획득한 값의 평균값을 구하였으며, 그 결과를 하기 표 6에 나타내었다.
The measurement was performed for each of 20 people, the average value of the values obtained from them was obtained, and the results are shown in Table 6 below.
(2) 피부자극도 평가(2) Evaluation of skin irritation degree
오르가노겔을 직경 10 mm 크기의 원형으로 잘라서 건강한 여성 20명의 팔 상박의 내측에 붙이고 24시간 후 떼어내어, 육안으로 피부의 상태를 파악하여 아래의 평가 기준에 따라 평가하였으며, 그 결과를 하기 표 6에 나타내었다.
Organogel was cut into a 10 mm diameter circle, attached to the inner arm upper arm of 20 healthy women, detached after 24 hours, and visually evaluated the condition of the skin and evaluated according to the following evaluation criteria. 6 is shown.
◎: 자극 없음◎: No stimulation
○: 약한 자극○: weak stimulus
□: 홍반 □: Erythema
△: 홍반 및 부종Δ: erythema and edema
X: 홍반, 부종 및 수포
X: Erythema, edema and blisters
(3) 안정성(변색, 겔강도, 상분리) 평가(3) Evaluation of stability (discoloration, gel strength, phase separation)
오르가노겔을 25℃의 공기 중에 방치하면서 시간 별로 60분, 5시간, 10시간, 24시간의 경과에 따라 오르가노겔의 물리적 변화를 육안으로 측정하여 아래의 평가 기준에 따라 평가하였으며, 그 결과를 하기 표 6에 나타내었다.
While leaving the organogel in air at 25 ° C, the physical change of the organogel was visually measured with the passage of 60 minutes, 5 hours, 10 hours, 24 hours, and evaluated according to the following evaluation criteria. It is shown in Table 6 below.
◎: 성상 유지◎: Maintain property
○: 전체면적 중 10% 미만으로 변색, 겔 강도(무름), 상분리○: less than 10% of total area, discoloration, gel strength (dryness), phase separation
□: 전체면적 중 30% 미만으로 변색, 겔 강도(무름), 상분리□: Less than 30% of the total area shows discoloration, gel strength (dryness), phase separation
△: 전체면적 중 50% 미만으로 변색, 겔 강도(무름), 상분리?: Less than 50% of the total area, discoloration, gel strength (dryness), phase separation
X: 전체면적 중 80% 미만으로 변색, 겔 강도(무름), 상분리
X: Less than 80% of the total area, discoloration, gel strength (dryness), phase separation
Corneometer 값 (AU)Early
Corneometer Value (AU)
Corneometer 값 (AU)30 minutes later
Corneometer Value (AU)
(g/m2h)Initial Tewarmeter Value
(g / m 2 h)
Tewarmeter 값 (g/m2h)30 minutes later
Tewarmeter value (g / m 2 h)
상기 표 6에서 나타난 바와 같이, 본 발명의 실시예 1 내지 4는 보습도, 피부자극도 및 안정성이 우수함을 확인할 수 있다. 반면, 비교예 1 은 보습도, 피부자극도 및 안정성이 붕충분하였으며, 비교예 2는 제형 자체가 불가능하여 물성을 측정할 수 없었다.
As shown in Table 6, Examples 1 to 4 of the present invention can be confirmed that the excellent moisturizing degree, skin irritation degree and stability. On the other hand, in Comparative Example 1, the moisturizing degree, skin irritation degree and stability were insufficient, and Comparative Example 2 was unable to measure the physical properties of the formulation itself.
(4) 경피 흡수 효율 평가(4) evaluation of transdermal absorption efficiency
헤어리스 마우스의 피부를 이용해 인비트로(in vitro) 피부 투과 시험을 수행하였다. 직경 15.0mm의 마우스 피부 표면에 실시예 3 및 4와 비교예 1의 시료를 각각 48마이크로리터 도포하고, 경피흡수기기(Hanson Microette)를 이용하여 24시간 후에 투과된 토코페롤아세테이트 양을 액체크로마토그래피로 정량하여, 그 결과를 하기 표 7에 나타내었다. 하기 표 7에 나타난 바와 같이, 본 발명에 따른 실시예 3 및 4의 경피 흡수 효율이 비교예 1보다 우수한 것을 확인할 수 있다.
In vitro skin penetration tests were carried out using the skin of hairless mice. 48 microliters of the samples of Examples 3 and 4 and Comparative Example 1 were respectively applied to the surface of the mouse skin having a diameter of 15.0 mm, and the amount of tocopherol acetate permeated after 24 hours using a Hanson Microette was analyzed by liquid chromatography. Quantification, the results are shown in Table 7 below. As shown in Table 7, it can be seen that the transdermal absorption efficiency of Examples 3 and 4 according to the present invention is superior to Comparative Example 1.
(5) 주름 개선 평가(5) wrinkle improvement evaluation
40~60 세의 여성 20 명을 대상으로 1 일 2 회씩 상기 실시예 3및 4와 비교예1에 따라 제조한 오르가노겔을 눈 주위에 20 mm 크기의 원형으로 균일하게 부착하였고, 측정 부위를 눈가주름(crow's feet)으로 정하여 총 3개월 동안 실험을 실시하였다. 피시험자의 왼쪽 눈가에는 상기 실시예 3 또는 4에서 제조한 오르가노겔을 적용하였고, 오른쪽 눈가에는 상기 비교예 1에서 제조한 조성물을 적용하였다.
Organogels prepared according to Examples 3 and 4 and Comparative Example 1 were uniformly attached in a round shape of 20 mm around the eyes twice a day for 20 women aged 40 to 60 years. The experiment was conducted for a total of 3 months, which was defined as crow's feet. The organogel prepared in Example 3 or 4 was applied to the left eye of the test subject, and the composition prepared in Comparative Example 1 was applied to the right eye.
오르가노겔을 부착한3 개월 후 주름의 완화 정도를 육안 판정(대조군과 비교하여 개선 없음, 약간의 개선, 중등도의 개선, 상당한 개선의 4 단계로 판정)하여 그 결과를 하기 표 8에 나타내었다.
Three months after the organogel was applied, the degree of wrinkles was visually determined (no improvement, slight improvement, moderate improvement, and significant improvement compared with the control group), and the results are shown in Table 8 below. .
나아가 오르가노겔의 적용 전과 후의 눈가 주름 주형(replica)과 관련하여 영상분석법을 이용하여 주름의 깊이(㎛)를 측정하고, 그 결과 주름 깊이 감소율을 하기 표 9에 나타내었다.
Furthermore, the depth of wrinkles (μm) was measured by using an image analysis method in relation to the eye wrinkle wrinkle (replica) before and after application of the organogel, and as a result, the wrinkle depth reduction rate is shown in Table 9 below.
상기 표 8 및 9에 나타난 바와 같이, 본 발명에 따라 제조된 오르가노겔은 경피 흡수 효율이 후수하며, 주름 개선에도 효과가 있는 것을 확인할 수 있다. As shown in Tables 8 and 9, the organogel prepared according to the present invention can be confirmed that the transdermal absorption efficiency is excellent and also effective in improving wrinkles.
Claims (16)
및 지지체를 포함하며,
상기 오르가노겔층은 상기 지지체 상에 0.01 내지 50mm의 두께로 코팅된 오르가노겔 마스크팩.
Purified water 53.62%, EDTA 2Na 0.01%, sorbitol 0.5%, methylparaben 0.2%, alpha bisabolol 2%, glycerin 8%, glucomannan 1.2%, carrageenan 0.45%, isopropyl myristate 30% An organogel layer formed of an organogel composition comprising%, 4% by weight of pluronic lecithin and 0.02% by weight of butylene / ethylene / styrene copolymer;
And a support,
The organogel layer is an organogel mask pack coated with a thickness of 0.01 to 50mm on the support.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120047564A KR101384999B1 (en) | 2012-05-04 | 2012-05-04 | Organogel Composition and Organogel Mask Pack using Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120047564A KR101384999B1 (en) | 2012-05-04 | 2012-05-04 | Organogel Composition and Organogel Mask Pack using Thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130126841A KR20130126841A (en) | 2013-11-21 |
KR101384999B1 true KR101384999B1 (en) | 2014-04-14 |
Family
ID=49854648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20120047564A KR101384999B1 (en) | 2012-05-04 | 2012-05-04 | Organogel Composition and Organogel Mask Pack using Thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101384999B1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105407870A (en) * | 2013-07-25 | 2016-03-16 | 詹尼克公司 | Organogel composition and organogel mask pack produced by using same |
CN105395412A (en) * | 2015-12-04 | 2016-03-16 | 周建忠 | Moisturizing facial mask |
FR3052070B1 (en) * | 2016-06-06 | 2019-09-13 | Mirei International Ltd | ORAL SKIN CARE OF NATURAL ORIGIN PROTECTING AGAINST EXTERNAL AND REGULATORY ATTACK EFFECTS BY ACTIVATION OF GENE EXPRESSION OF EPIDERMAL GROWTH FACTORS (EGF) |
KR101723183B1 (en) * | 2016-11-17 | 2017-04-05 | 주식회사 케이티에이치아시아 | Skin temperature sensitive hydro oil gel manufacturing method |
CN107374983A (en) * | 2017-07-05 | 2017-11-24 | 北京化工大学 | A kind of composite fibre facial mask rich in collagen and preparation method thereof |
CN107693459A (en) * | 2017-11-30 | 2018-02-16 | 安徽澳聪食品有限公司 | One kind self-control Aloe Vera Gel and preparation method thereof |
KR102017619B1 (en) * | 2017-12-08 | 2019-09-04 | 스킨큐어 주식회사 | Composition for Anti-Inflammation Anti-Pruritus, Skin Moisturizing and Skin Suppression |
KR101981696B1 (en) * | 2017-12-18 | 2019-05-29 | (주)아미드팩토리 | Mist Composition comprising natural complex extracts |
KR102184802B1 (en) * | 2019-01-25 | 2020-12-01 | 제주대학교 산학협력단 | Pluronic Lecithin Organogel composition with improved storage stability at low temperature |
KR102241402B1 (en) * | 2019-01-30 | 2021-04-16 | (주) 제이엠피바이오 | Production method for gel type cosmetic composition and cosmetic composition thereof |
CN114344197B (en) * | 2022-01-13 | 2023-06-09 | 惠州市栢诗新材料有限公司 | Medical cold compress repair mask containing argan oil and preparation method of medical cold compress repair mask |
KR102472487B1 (en) * | 2022-06-14 | 2022-12-01 | (주)올바름디앤비 | Cosmetic composition comprising natural extract mixture |
KR102656691B1 (en) * | 2024-01-11 | 2024-04-09 | 김석오 | Silicone mask that emits negative ion and far-infrared ray to reduce pore and prevent skin aging |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010049500A (en) * | 1999-06-21 | 2001-06-15 | 조지안느 플로 | Organogels and uses, in particular cosmetic uses, thereof |
KR20030014700A (en) * | 2000-06-13 | 2003-02-19 | 히사미쓰 세이야꾸 가부시키가이샤 | Plaster |
-
2012
- 2012-05-04 KR KR20120047564A patent/KR101384999B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010049500A (en) * | 1999-06-21 | 2001-06-15 | 조지안느 플로 | Organogels and uses, in particular cosmetic uses, thereof |
KR20030014700A (en) * | 2000-06-13 | 2003-02-19 | 히사미쓰 세이야꾸 가부시키가이샤 | Plaster |
Also Published As
Publication number | Publication date |
---|---|
KR20130126841A (en) | 2013-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101384999B1 (en) | Organogel Composition and Organogel Mask Pack using Thereof | |
KR20140109804A (en) | Liquid Crystal Emulsified Organogel Composition and Mask Pack using Thereof | |
KR102055150B1 (en) | Intercellular Lipids Mimetic Composition with Improved Transdermal Absorption, Method for Preparing Same, and Hydrogel Mask Pack Containing Same | |
JP5953376B2 (en) | Emulsified hydrogel composition and method for producing the same | |
CN105407870A (en) | Organogel composition and organogel mask pack produced by using same | |
EP2921164A1 (en) | Sticky hydrogel cosmetic composition | |
JP4767914B2 (en) | Cosmetic composition that has an effect of tightening the skin | |
KR102555803B1 (en) | Hydrogel Capsule, Preparation Method Thereof and Cosmetic Composition Comprising The Same | |
EP2913046A1 (en) | Oil-in-water form organogel cosmetic composition having variable transparency | |
KR20120042396A (en) | Nanoemulsion cosmetic composition produced by using polyglyceryl ester alone as an emulsifier and the method for preparing thereof | |
CA2750146C (en) | Matte skin finish compositions | |
KR101370328B1 (en) | Immproved feeling and Hydrating effect Water-in-silicone and Silicone-in-water emulsion type using the poly-ionic complex in oil soluble ingredient | |
JP2022022389A (en) | How to treat signs of skin aging and how to moisturize the skin | |
KR100912242B1 (en) | Nanoemulsions Containing Lecithin and Polyglycerin Fatty Acid Esters and Moisturizer Compositions Comprising the Same | |
CN113226254B (en) | Oil-in-water emulsion cosmetic containing retinol | |
CN112716823A (en) | High-moisture-retention moisture gel cream and preparation method thereof | |
KR102432885B1 (en) | Cosmetic composition for anti-aging | |
US20070148219A1 (en) | Liposomal Nanowater-Containing Patch-Type Nanodermal Gel for Transdermal Delivery and Method for Preparing the Same | |
KR101011356B1 (en) | Stick type cosmetic composition containing rosemarine acid | |
KR20160071744A (en) | Thermo-sensitive color cosmetic composition and the method of producing the same | |
US20240009644A1 (en) | Method for preparing multilayer spherical particles and cosmetic composition comprising multilayer spherical particles prepared thereby | |
KR102485847B1 (en) | A cosmetic composition capable of changing the shape from an emulsified cream state to a mist state | |
KR102211754B1 (en) | Elongational cosmetic composition with shape restoration ability and manufacturing method thereof | |
CN117427009A (en) | Transparent oil-in-water type skin care product without emulsifier and preparation method thereof | |
KR20220033294A (en) | Method for producing cosmetic composition comprising powder mixture with oil as a binder, and cosmetic composition produced thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20120504 |
|
PA0201 | Request for examination | ||
A302 | Request for accelerated examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20130509 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20120504 Patent event code: PA03021R01I Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130827 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20131223 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20140328 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20140408 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20140408 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20170308 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20170308 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190318 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20190318 Start annual number: 6 End annual number: 6 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20210119 |